Melanoma is different from most skin cancer diagnoses. A Stage I melanoma, caught early, is treated with surgery and in most cases results in cure. A Stage III or IV melanoma involves systemic treatment, significant costs, and a very different medical aid experience. Where you fall on that spectrum determines your next steps. This guide gives you both paths clearly.
First: Your PMB Protection
Melanoma is a PMB condition. Your medical aid must fund your diagnosis, staging, and treatment — regardless of your plan or any waiting periods for other conditions. The coverage questions are about depth and cost exposure, not whether you are covered at all.
Step 1: Understand Your Stage
Before you can plan for your medical aid, you need to know your stage. This comes from:
- The excisional biopsy: Breslow thickness (depth of tumour in mm) and ulceration status determine the T-stage.
- Sentinel lymph node biopsy (SLNB): For tumours >0.8mm thick, SLNB checks whether melanoma has spread to the nearest lymph node. A positive SLNB means Stage III.
- Staging scans (CT, PET/CT): If Stage III is confirmed or Stage IV is suspected.
Your stage determines the entire cost trajectory of your treatment. Stage I costs are modest and usually well-covered. Stage III–IV treatment requires active exceptional-needs management.
Step 2: Call Your Scheme — Oncology Case Management
Call your medical aid and ask to be transferred to oncology case management. Tell them:
- You have been diagnosed with melanoma.
- You need to register your PMB oncology benefit.
- Ask for a dedicated case manager to be assigned.
For Stage I–II patients: this registration ensures surgery and staging are correctly processed as PMB. For Stage III–IV patients: this case manager becomes your point of contact for all pre-authorisations and exceptional-needs applications throughout treatment.
Step 3: Find Your Oncology Sub-Limit
Ask your case manager or check your benefit guide for your annual oncology sub-limit. For melanoma, this matters enormously by stage:
- Stage I–II (surgery only): Most plans are adequate. Surgical procedure + SLNB + follow-up: R50,000–R100,000 total.
- Stage III (adjuvant immunotherapy): Adjuvant pembrolizumab for 12 months costs R500,000–R800,000 — a plan with a R300,000 sub-limit is severely inadequate.
- Stage IV (systemic treatment): Costs can reach R700,000–R1,200,000+ per year. Very few standard comprehensive plans have sub-limits that cover this.
If you are Stage III or IV and your plan's sub-limit appears insufficient, explore moving to a higher-option plan within your scheme before treatment starts. Option changes within the same scheme do not trigger new waiting periods for the existing diagnosis.
Step 4: BRAF Mutation Testing — Do Not Skip This
If you are Stage III or IV, your oncologist will order BRAF mutation testing (specifically BRAF V600E/K) on your tumour tissue. This test determines whether targeted therapy (dabrafenib + trametinib) is an option for you.
- Approximately 50% of cutaneous melanomas carry a BRAF mutation.
- If BRAF-positive: targeted therapy is first-line or concurrent with immunotherapy.
- If BRAF-negative: immunotherapy (pembrolizumab, nivolumab, or combination ipilimumab + nivolumab) is the primary option.
Whether your scheme funds this test is not guaranteed. Some schemes fund molecular testing as part of the PMB diagnostic workup; others do not. Cost is approximately R4,000–R8,000 per BRAF test. Pay for it if necessary — the result directly determines your treatment protocol.
Step 5: Start Exceptional-Needs Applications Early
For Stage III–IV, the medicines you need (pembrolizumab, nivolumab, dabrafenib, trametinib) are not automatically PMB-funded. They require exceptional-needs authorisation. Your oncologist submits the motivation; you track it.
What to do: 1. Ask your oncologist to submit the exceptional-needs application at the same time as your PMB registration — not weeks later. 2. Ensure the motivation includes: BRAF result, staging data, pathology report, and explanation of why the standard PMB treatment (dacarbazine chemotherapy) is clinically inferior. 3. Follow up with your case manager weekly if approval has not been received. 4. If declined: request written reasons, have your oncologist strengthen the motivation, and submit a formal appeal.
The earlier this is started, the less likely you are to face a gap where treatment is delayed while waiting for authorisation.
Step 6: Should You Switch Plans?
For Stage I–II patients, your current plan is probably adequate — confirm by checking the sub-limit against your expected costs. For Stage III–IV patients, the honest answer is:
- Most mid-tier plans (R250,000–R400,000 sub-limits) are inadequate for systemic melanoma treatment.
- If you are diagnosed before the October–November open-enrolment window, you may be able to move to a plan with a higher sub-limit or unlimited oncology for the following year.
- Do not move to a new scheme entirely — pre-existing condition waiting periods make this extremely high-risk during active treatment.
Emergency and Support Resources
CANSA (Cancer Association of SA): 0800 22 6622 (toll-free, weekdays) Melanoma SA: melanomasa.co.za Council for Medical Schemes (CMS): 0861 123 267 | www.medicalschemes.co.za For PMB disputes or scheme appeals.
What AURA Does Differently
AURA calculates your actual annual cost on each plan — oncology sub-limit, exceptional-needs track record, specialist network — so you can see whether your plan is adequate for Stage III–IV melanoma, not just for a standard skin condition.
Get help understanding your cover options →